News Column

Findings from National Health Service in the Area of Cancer Vaccines Reported (Exosomes as Immunotheranostic Nanoparticles)

August 4, 2014



By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Investigators discuss new findings in Immunization. According to news reporting out of London, United Kingdom, by NewsRx editors, research stated, "Exosomes are small biological membrane vesicles that measure 30 to 100 nm in diameter. They are involved in a wide array of biological activities, such as cell-cell communication, signal transduction, transport of genetic materials, and modulation of immune response."

Our news journalists obtained a quote from the research from National Health Service, "Evidence indicates that they can be used as not only therapeutic agents targeted against disease but also diagnostic biomarkers for pathologic conditions. In this review, we endeavor to present exosomes as immunologic agents that can be used as pioneering cancer vaccines to prime the immune system and explicate their therapeutic and diagnostic capabilities. An extensive literature search for studies that involved the use of exosomes as immunotheranostic nanoparticles was conducted using PubMed, IST Web of Knowledge, and Google Scholar. Clinical trials that involved exosomes were also compiled by searching the clinicaltrials.gov database. In its therapeutic facet of application, exosomes can be used as vehicles for drug or gene delivery. These biological vesicles have been found to have excellent host biodistribution and biocompatibility, issues often presented with gene delivery vehicles. Diagnostically, exosomes may prove to be useful biomarkers that are able to surpas current setbacks of modern diagnostic testing, which include invasive methods. Finally, current evidence has implied that the use of exosomes could form the basis for the development of future cell-free cancer vaccines."

According to the news editors, the research concluded: "Exosomes have numerous functions, and their double-edged features make the scope of their clinical applications, as both a diagnostic and therapeutic tool, immense."

For more information on this research see: Exosomes as Immunotheranostic Nanoparticles. Clinical Therapeutics, 2014;36(6):820-829. Clinical Therapeutics can be contacted at: Elsevier, 685 Route 202-206, Bridgewater, NJ 08807, USA. (Elsevier - www.elsevier.com; Clinical Therapeutics - www.elsevier.com/wps/product/cws_home/525050)

Our news journalists report that additional information may be obtained by contacting G. Natasha, Royal Free London Natl Hlth Serv Fdn Trust Hosp, London, United Kingdom. Additional authors for this research include B. Gundogan, A. Tan, Y. Farhatnia, W. Wu, J. Rajadas and A.M. Seifalian (see also Immunization).

Keywords for this news article include: Biotechnology, London, Europe, Exosomes, Organelles, Immunization, Nanoparticle, United Kingdom, Bioengineering, Nanotechnology, Cancer Vaccines, Transport Vesicles, Biological Products, Cancer Gene Therapy, Emerging Technologies, Cytoplasmic Structures

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Gene Therapy Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters